Actively Recruiting
Evaluating Kedrion Intravenous Immunoglobulin 10% in Adults with Chronic Primary Immune Thrombocytopenia A Phase III Open-label Multicenter Study
Led by Kedrion S.p.A. · Updated on 2026-10-22
40
Participants Needed
28
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Kedrion IVIg 10%, an intravenous human normal immunoglobulin, in adults with chronic primary immune thrombocytopenia ITP. This Phase III trial focuses on patients aged 18 to 70 who have had chronic ITP for more than 12 months and low platelet counts. The study aims to assess how well the treatment helps increase platelet levels and control bleeding symptoms. Participants will receive a single course of Kedrion IVIg 10% at a dose of 2 gkg administered intravenously over two days. This open-label, single-arm study does not include a comparison group. Treatment response and safety will be monitored through several assessments performed from the day of treatment up to 30 days after. During the study, participants will undergo platelet count tests, bleeding assessments, and safety evaluations from the first day through 30 days post-treatment. Researchers will measure response rates by day 14 and track the duration of response and reduction in hemorrhages. The total participation period extends from treatment day to the end of follow-up at 30 days, ensuring monitoring of both effectiveness and tolerability.
CONDITIONS
Brief Title
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Research Team
A
Anna Lotti Suffredini
L
Linda Karpiak
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here